Opinion

Video

SunRISe-1: Examining Combination Therapy for HR NMIBC

1) A medical urologist discusses the rationale and design of the SunRISe-1 phase 2 trial, which evaluates the combination of intravesical TAR-200 and systemic cetrelimab, as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC), focusing on key efficacy and safety endpoints.

Discuss the rationale and design of the SunRISe-1 phase 2 trial evaluating the combination of intravesical TAR-200 and systemic cetrelimab,as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC). What are the key efficacy and safety endpoints?

Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo